Hansa Biopharma Welcomes Maria Törnsén as New COO and U.S. President
Hansa Biopharma Welcomes Maria Törnsén as New COO and U.S. President
Hansa Biopharma AB, a leading biopharmaceutical company, has recently announced the appointment of Maria Törnsén as Chief Operating Officer (COO) and President of the U.S. operations, starting May 19, 2025. This strategic move comes as part of Hansa's efforts to advance its mission to develop and commercialize innovative treatments for patients suffering from rare immunological conditions.
Maria Törnsén brings over two decades of invaluable experience in the pharmaceutical sector, particularly in global and U.S. operations. Before joining Hansa, she held the position of President North America at Calliditas Therapeutics, where she successfully led the U.S. commercial and medical affairs organization until its acquisition by Asahi Kasei Corporation in September 2024. Törnsén has also held senior leadership roles at various notable companies, including Sarepta Therapeutics, where she worked as the Senior Vice President and U.S. General Manager, and Sanofi Genzyme, where she served as the Vice President and Global Therapeutic Area Head.
During her remarkable career, Ms. Törnsén has accomplished the launch of numerous products in the U.S. market and has dramatically influenced a global franchise worth $1.6 billion. Currently, she serves on the board of directors for Immunic Therapeutics and holds a Master of Science in International Business Administration from Lund University in Sweden.
The CEO of Hansa Biopharma, Renée Aguiar-Lucander, expressed enthusiasm about Törnsén's arrival: “We are pleased to welcome Ms. Törnsén to the executive management team as COO and President of the U.S. business. She brings invaluable experience in the area of rare diseases and gene therapy, from building commercial organizations, launching new products and driving growth and profitability, which will be critical as we prepare for the next phase of our development.”
Törnsén herself shared her excitement, stating, “I am delighted to join Hansa at this exciting time in the company's history. I look forward to working with the Hansa team and leveraging my experience from prior roles to support the continued growth of IDEFIRIX and prepare for multiple anticipated catalysts in the second half of 2025.”
Hansa Biopharma, headquartered in Lund, Sweden, is dedicated to addressing unmet medical needs through its innovative IgG-cleaving enzyme technology platform. The company's flagship product, imlifidase, represents a groundbreaking therapy aimed at enabling kidney transplantation for highly sensitized patients, affirming Hansa's commitment to advancing the field of immunology.
As Hansa Biopharma moves forward under Maria Törnsén's leadership, the company looks to not only enhance its operational capacities but also to continue making significant strides in developing therapies for rare diseases. The company operates in both Europe and the U.S., reflecting its commitment to serving patients globally with innovative solutions.
In closing, As Hansa Biopharma embarks on this new chapter with Törnsén at the helm of U.S. operations, stakeholders and patients can remain optimistic about the company's future endeavors and contributions to the field of biopharmaceuticals. Stay tuned for updates as Hansa gears up for another exciting phase in its journey to improve the lives of patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.